

Resource Summary Report

Generated by [NIF](#) on Aug 26, 2026

Fred Hutchinson Cancer Center Experimental Histopathology Core Facility

RRID:SCR_022612

Type: Tool

Proper Citation

Fred Hutchinson Cancer Center Experimental Histopathology Core Facility
(RRID:SCR_022612)

Resource Information

URL: <https://www.fredhutch.org/en/research/shared-resources/core-facilities/experimental-histopathology.html>

Proper Citation: Fred Hutchinson Cancer Center Experimental Histopathology Core Facility (RRID:SCR_022612)

Description: Provides expertise in anatomic pathology technologies. Offers routine and special staining, ? immunohistochemistry, in situ hybridization and digital pathology in support of internal and external investigators who rely on histological analysis.

Synonyms: Fred Hutchinson Cancer Center Experimental Histopathology Shared Resource

Resource Type: access service resource, core facility, service resource

Keywords: anatomic pathology technologies, staining, ? immunohistochemistry, in situ hybridization, digital pathology, ABRF, USEDit, NACCSR

Availability: Open

Resource Name: Fred Hutchinson Cancer Center Experimental Histopathology Core Facility

Resource ID: SCR_022612

Alternate IDs: ABRF_1534

Alternate URLs: https://coremarketplace.org/RRID:SCR_022612/?citation=1

Record Creation Time: 20220802T050144+0000

Record Last Update: 20260821T194228+0000

Ratings and Alerts

No rating or validation information has been found for Fred Hutchinson Cancer Center Experimental Histopathology Core Facility.

No alerts have been found for Fred Hutchinson Cancer Center Experimental Histopathology Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Chhan CB, et al. (2026) Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development. Cell reports. Medicine, 7(2), 102618.

Zhang S, et al. (2026) A CD8?? co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands. Nature communications, 17(1), 753.

Liu Y, et al. (2026) Therapeutic scheduling of WEE1 inhibition preserves T cell function and promotes immune control of HPV+ tumors. bioRxiv : the preprint server for biology.

Talavera IC, et al. (2026) Regulatory T cells restrain IL-15-mediated cytotoxic and bystander T cell activity in mucosal tissue without compromising antigen-driven memory. bioRxiv : the preprint server for biology.

Hagen MW, et al. (2026) The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy. Blood advances, 10(7), 2452.

Taber A, et al. (2026) Human lung ?? T cells maintain functionality during inflammatory lung disease. bioRxiv : the preprint server for biology.

Loroña NC, et al. (2026) Site- and age-dependent associations between Fusobacterium nucleatum and colorectal cancer mortality. Cancer, 132(12), e70484.

Gianopoulos JE, et al. (2026) ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer. Nature communications, 17(1).

Vick SC, et al. (2025) Mucosal tissue NK cells tune their function between optimal anti-pathogen activity and tissue protection. bioRxiv : the preprint server for biology.

Granadier D, et al. (2025) Damage-induced IL-18 stimulates thymic NK cells limiting endogenous tissue regeneration. *Nature immunology*, 26(10), 1699.

Choe M, et al. (2025) Preclinical Evaluation of Folate Receptor- α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma. *Cancer research communications*, 5(9), 1701.

Rominger MC, et al. (2025) Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state. *Cell reports*, 44(10), 116185.

Semenova G, et al. (2025) Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. *bioRxiv : the preprint server for biology*.

Gregorio NE, et al. (2025) PhoCoil: A photodegradable and injectable single-component recombinant protein hydrogel for minimally invasive delivery and degradation. *Science advances*, 11(35), eadx3472.

Figueiredo JC, et al. (2025) The Translational Research Program in Cancer Differences across Populations. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research*, cosponsored by the American Society of Preventive Oncology, 34(9), 1472.

Garcia NMG, et al. (2025) APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer. *Cancer research communications*, 5(5), 825.

Gómez-Garzón C, et al. (2025) Metaplasia Enables Stomach Colonization by *Fusobacterium animalis*. *bioRxiv : the preprint server for biology*.

Sabo MC, et al. (2025) Bacterial Vaginosis Is Associated With Transcriptomic Changes but Not Higher Concentrations of Cervical Leukocytes in a Study of Women at High Risk for Human Immunodeficiency Virus Acquisition. *The Journal of infectious diseases*, 231(6), 1407.

Damle SR, et al. (2025) Intratumoral three-cell-type clusters are a conserved feature of endogenous antitumor immunity. *Cancer immunology research*.

An J, et al. (2025) Neuronal TDP-43 pathology drives astrocytic interferon response in a mouse model of ALS. *Journal of neuroinflammation*.